

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

20350

7590

01/30/2004

TOWNSEND AND TOWNSEND AND CREW, LLP TWO EMBARCADERO CENTER EIGHTH FLOOR SAN FRANCISCO, CA 94111-3834 EXAMINER SALIMI, ALI REZA

ART UNIT

PAPER NUMBER

1648

DATE MAILED: 01/30/2004

	APPLICATION NO.	FILING DATE	ING DATE FIRST NAMED INVENTOR		CONFIRMATION NO.
•	10/087.882	03/01/2002	Sved Z. Salahuddin	015280-212210US	8486

TITLE OF INVENTION: ANTIBODIES AGAINST HUMAN HERPES VIRUS-6(HHV-6) AND METHOD OF USE

APPLN. TYPE	SMALL ENTITY	ISSUE FEE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
 nonprovisional	NO	\$1330	\$0	\$1330	04/30/2004

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. <u>PROSECUTION ON THE MERITS IS CLOSED</u>. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE REFLECTS A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE APPLIED IN THIS APPLICATION. THE PTOL-85B (OR AN EQUIVALENT) MUST BE RETURNED WITHIN THIS PERIOD EVEN IF NO FEE IS DUE OR THE APPLICATION WILL BE REGARDED AS ABANDONED.

HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

- A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.
- B. If the status is changed, pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above and notify the United States Patent and Trademark Office of the change in status, or

If the SMALL ENTITY is shown as NO:

- A. Pay TOTAL FEE(S) DUE shown above, or
- B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check the box below and enclose the PUBLICATION FEE and 1/2 the ISSUE FEE shown above.
- ☐ Applicant claims SMALL ENTITY status. See 37 CFR 1.27.
- II. PART B FEE(S) TRANSMITTAL should be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). Even if the fee(s) have already been paid, Part B Fee(s) Transmittal should be completed and returned. If you are charging the fee(s) to your deposit account, section "4b" of Part B Fee(s) Transmittal should be completed and an extra copy of the form should be submitted.
- III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail

Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

maintenance fee notifications.

(703) 746-4000 or Fax INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 4 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for CURRENT CORRESPONDENCE ADDRESS (Note: Legibly mark-up with any corrections or use Block 1) Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission. 20350 7590 01/30/2004 TOWNSEND AND TOWNSEND AND CREW, LLP Certificate of Mailing or Transmission I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO, on the date indicated below. TWO EMBARCADERO CENTER **EIGHTH FLOOR** SAN FRANCISCO, CA 94111-3834 (Dépositor's name (Signature (Date) CONFIRMATION NO. APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. 10/087,882 03/01/2002 Syed Z. Salahuddin 015280-212210US 8486 TITLE OF INVENTION: ANTIBODIES AGAINST HUMAN HERPES VIRUS-6(HHV-6) AND METHOD OF USE **PUBLICATION FEE** TOTAL FEE(S) DUE DATE DUE APPLN, TYPE SMALL ENTITY **ISSUE FEE** \$1330 04/30/2004 NO \$1330 \$0 nonprovisional **EXAMINER** ART UNIT CLASS-SUBCLASS 435-007200 SALIMI, ALI REZA 1648 l. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). 2. For printing on the patent front page, list (1) the names of up to 3 registered patent attorneys or agents OR, alternatively, (2) the name of a single $\ensuremath{\mathbf{Q}}$ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. ١. firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent "Fee Address" indication (or "Fee Address" Indication form attorneys or agents. If no name is listed, no name PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer will be printed. Number is required. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. Inclusion of assignee data is only appropriate when an assignment has been previously submitted to the USPTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) ☐ individual • corporation or other private group entity Please check the appropriate assignee category or categories (will not be printed on the patent); government 4a. The following fee(s) are enclosed: 4b. Payment of Fee(s): ☐ Issue Fee ☐ A check in the amount of the fee(s) is enclosed. ☐ Payment by credit card. Form PTO-2038 is attached. Publication Fee ☐ The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number ______ (enclose an extra copy of this form). □ Advance Order - # of Copies _ Director for Patents is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. (Authorized Signature) (Date)

NOTE; The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office. This collection of information is required by 37 CFR 1.311. The information is required to

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents. Alexandria, Virginia 22313-1450. SEND TO: Commissioner for Patents, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/087,882	03/01/2002	Syed Z. Salahuddin	015280-212210US	8486
20350	7590 01/30/2004		EXAMINER	
TOWNSEND AND TOWNSEND AND CREW, LLP			SALIMI, ALI REZA	
TWO EMBARC	ADERO CENTER			
EIGHTH FLOOF	}		ART UNIT	PAPER NUMBER
SAN FRANCISC	ANCISCO, CA 94111-3834		1648	
			DATE MAILED: 01/30/2004	

Determination of Patent Term Extension or Adjustment under 35 U.S.C. 154 (b)

A reissue patent is for "the unexpired part of the term of the original patent." See 35 U.S.C. 251. Accordingly, the above-identified reissue application is not eligible for Patent Term Extension or Adjustment under 35 U.S.C. 154(b).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (703) 305-1383. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at (703) 305-8283.

	Application No.	Applicant(s)			
•	Application No.	Applicant(s)			
Nation of Allamability	10/087,882	SALAHUDDIN ET AL.			
Notice of Allowability	Examiner	Art Unit			
	A R Salimi	1648			
Th MAILING DATE of this communication apperall claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIF	(OR REMAINS) CLOSED or other appropriate comm IGHTS. This application is	in this application. If not included nunication will be mailed in due co	ourse. THIS		
2. ☑ The allowed claim(s) is/are <u>1,2 and 4-12</u> .					
3. The drawings filed on 12 February 2003 are accepted by the	he Examiner.				
 Acknowledgment is made of a claim for foreign priority ur a) ☐ All b) ☐ Some* c) ☐ None of the: 		or (f).			
 Certified copies of the priority documents have 	e been received.				
2. Certified copies of the priority documents have	been received in Applicati	on No	•		
3. Copies of the certified copies of the priority do	cuments have been receive	ed in this national stage applicatio	n from the		
International Bureau (PCT Rule 17.2(a)).					
* Certified copies not received: 5. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78. (a) The translation of the foreign language provisional application has been received. 6. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.					
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.					
7. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.					
 8. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted. (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) ☐ hereto or 2) ☐ to Paper No 					
(b) 🔲 including changes required by the proposed drawing correction filed, which has been approved by the Examiner.			miner.		
(c) ☐ including changes required by the attached Examiner's	s Amendment / Comment o	or in the Office action of Paper No	··		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the margin according to 37 CFR 1.121(d).					
9. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.					
Attachm nt(s)	·				
1☐ Notice of References Cited (PTO-892)	5 ☐ Notice of In	formal Patent Application (PTO-15	52)		
2☐ Notice of Draftperson's Patent Drawing Review (PTO-948)		ummary (PTO-413), Paper No	·		
3 ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No	3), 7 ⊠ Examiner's	Amendment/Comment			
4☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	8∏ Examiner's 9∏ Other	Statement of Reasons for Albawar	nce		
		Statement of Reasons for Albavar			

Art Unit: 1648

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Ms. Carol Fang on 1/5/2003.

The application has been amended as follows:

1. (Amended three times) An isolated antibody which specifically binds to an antigenic molecule from an isolated human herpes virus [having]

wherein said isolated human herpes virus has the morphology of a human herpes virus and a double-stranded DNA genome of about 170 Kb,

wherein genomic DNA from said isolated human herpes virus comprises a [hybridizes under stringent conditions with] nucleic acid sequence of molecular clone ZVH14 (ATCC Accession No. 40,247); and

further wherein said [first nucleic acid] <u>antibody</u> does not [hybridize under said stringent conditions with the nucleic acid of] <u>specifically bind to an antigenic molecule from</u>

- (a) Epstein-Barr virus;
- (b) human cytomegalovirus (CMV);
- (c) [I] Herpes Simplex virus (HSV);
- (d) Varicella-Zoster virus (VZV); or
- (e) Herpes virus saimiri.

Art Unit: 1648

Replaced the paragraph beginning at col. 1, line 1 with the following paragraph:

---This is a reissue of application Serial No. 08/774,118 filed Dec. 23, 1996 (now U.S. patent No. 6,054,283) which was a divisional of application Serial No. 08/392,674, filed Feb. 22, 1995 (now U.S. Pat. No. 5,604,093), which was [This is] a continuation of Ser. No. 07/754,220, filed Aug. 27, 1991 (now abandoned), which was a continuation of Ser. No. 07/255,712, filed Oct. 11, 1988 (now abandoned), which was a CIP of Ser. No. 07/228,550, filed Aug. 4, 1988 (now abandoned), which was a CIP of Ser. No. 06/901,602, filed Aug. 29, 1986 (now abandoned), which was a CIP of Ser. No. 06/892,423, filed Aug. 4, 1986 (now abandoned), which was a CIP of Ser. No. 06/895,857 filed Aug. 12, 1986, (now abandoned), which was a CIP of Ser. No. 06/895,857 filed Aug. 12, 1986, (now abandoned), which was a CIP of Ser. No. 06/895,463, filed Aug. 11, 1986, the disclosure of which is incorporated by reference.---

Claims 1, 2, 4-12 are allowed.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to A. R. Salimi whose telephone number is (703) 305-7136. The examiner can normally be reached on Monday-Friday from 9:00 Am to 6:00 Pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel, can be reached on (703) 308-4027. The Official fax number is (703) 872-9306.

Art Unit: 1648

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

A. R. Salimi

01/05/2004

Edwind Strange